Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches

Though it's still integrating its Celgene buy, Bristol Myers Squibb already looks quite different than it did this time last year. One reason for that? New drug launches that not only moved from the pipeline column to the FDA-approved portfolio, but also saw their rollouts revamped by the COVID-19 pandemic.